How to Measure Disease Activity, Impact, and Control in Patients with Recurrent Wheals, Angioedema, or Both.
Angioedema
Disease activity
Disease control
HAE
Patient-reported outcome
Quality of life
Urticaria
Journal
The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
18
12
2020
revised:
22
01
2021
accepted:
08
02
2021
entrez:
11
6
2021
pubmed:
12
6
2021
medline:
9
7
2021
Statut:
ppublish
Résumé
Chronic spontaneous urticaria and chronic inducible urticaria are characterized by wheals, angioedema, or both, whereas other conditions such as hereditary angioedema present only with angioedema. The unpredictability of outbreaks, disfigurement, pruritus, and associated sleep and work disturbance can cause a significant impact on quality of life (QoL). Significant breakthroughs in the understanding of these conditions in recent years have led to the development of novel therapies. Assessment of patients with these conditions not only focuses on the clinical activity of the condition, but also on the impact on QoL and disease control with treatment. Patient-reported outcome measures, especially if sufficiently validated, give due prominence to the patient's perspective regarding disease impact and treatment outcomes. This article will review the tools readily available to assess activity, impact, and control in patients with recurrent wheals, angioedema, or both.
Identifiants
pubmed: 34112471
pii: S2213-2198(21)00231-2
doi: 10.1016/j.jaip.2021.02.026
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2151-2157Informations de copyright
Copyright © 2021. Published by Elsevier Inc.